Investigation of Minimal Residual Disease in Childhood and Adult Acute Lymphoblastic Leukaemia by Molecular Analysis

Foroni, Letizia; Harrison, Christine J.; Hoffbrand, A. Victor; Potter, Michael

doi:10.1111/j.1365-2141.1999.01365.x

Cited by 105 publications

(25 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies have resulted in the introduction of new interventions to target this disease with the expectation of improved patient outcome (Faderl et al, 1999;Foroni et al, 1999;Hochhaus et al, 2000;Roman et al, 2000;Campana et al, 2001). Amplification of known tumour-specific gene rearrangements has also provided a powerful tool to detect potential significant MD in solid cancers including those of the Ewing's sarcoma family of tumours (de Alava et al, 1998;Zoubek et al, 1998;Schleiermacher et al, 2003;Avigad et al, 2004), alveolar rhabdomyosarcoma (Thomson et al, 1999;Athale et al, 2001;Gallego et al, 2006) and desmoplastic small round cell tumours (Athale et al, 2001).…”

Section: Optimal Target Selection For Detection Of MD By Rt -Pcrmentioning

confidence: 99%

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

et al. 2009

View full text Add to dashboard Cite

Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task Force has defined standardised methods for the determination of minimal disease (MD) by immunocytology (IC) and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) using disialoganglioside G D2 and tyrosine hydroxylase mRNA respectively. The INRG standard operating procedures (SOPs) define methods for collecting, processing and evaluating bone marrow (BM), peripheral blood (PB) and peripheral blood stem cell harvest by IC and QRT-PCR. Sampling PB and BM is recommended at diagnosis, before and after myeloablative therapy and at the end of treatment. Peripheral blood stem cell products should be analysed at the time of harvest. Performing MD detection according to INRG SOPs will enable laboratories throughout the world to compare their results and thus facilitate quality-controlled multi-centre prospective trials to assess the clinical significance of MD and minimal residual disease in heterogeneous patient groups.

show abstract

Section: Optimal Target Selection For Detection Of MD By Rt -Pcrmentioning

confidence: 99%

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

et al. 2009

View full text Add to dashboard Cite

show abstract

“…18 Among the available methods for MRD detection in ALL, flow cytometric analysis of abnormal immunophenotypes and polymerase chain reaction (PCR) amplification of antigen-receptor genes are the most widely used. 18,19 Both techniques can be applied to study clinical samples, can consistently detect one leukemic cell among 10 000 or more normal bone marrow mononuclear cells, [20][21][22] and have been shown to provide prognostically useful information. [1][2][3][4][5][6][8][9][10][11] Virtually all MRD studies reported to date have relied on one single technique.…”

Section: Introductionmentioning

confidence: 99%

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia

et al. 2004

View full text Add to dashboard Cite

Minimal residual disease (MRD) is an independent prognostic factor in childhood acute lymphoblastic leukemia (ALL). The most widely applied MRD assays in ALL are flow cytometric identification of leukemia immunophenotypes and polymerase chain reaction (PCR) amplification of antigen-receptor genes. We measured MRD by both assays in 227 patients with childhood B-lineage ALL. Of 1375 samples (736 bone marrow and 639 peripheral blood) examined, MRD was o0.01% in 1200, and X0.01% in 129 by both assays; MRD levels measured by the two methods correlated well. Of the remaining 46 samples, 28 had MRD X0.01% by flow cytometry but o0.01% by PCR. However, PCR (which had a consistent sensitivity of 0.001%) detected leukemic gene rearrangements in 26 of these 28 samples. Conversely, in 18 samples, MRD was X0.01% by PCR but o0.01% by flow cytometry. In nine of these samples, flow cytometry had a sensitivity of 0.001%, and detected aberrant immunophenotypes in eight samples. Therefore, the two most widely used methods for MRD detection in ALL yield concordant results in the vast majority of cases, although the estimated levels of MRD may vary in some. The use of the two methods in tandem ensures MRD monitoring in all patients.

show abstract

“…The most frequently used methods for MRD assessment are comparative hybridization and limiting dilution analysis. 6 Comparative hybridization is time-consuming, taking 2-3 days to complete. Further, data from these analyses are semi-quantitative.…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5] The consensus from MRD studies is that clinical evaluation of MRD should improve the overall cure rate of ALL by identifying the patients with highest risk of relapse thereby allowing timely therapeutic intervention. 6,7 The most common method for quantifying leukemic cells in ALL is polymerase chain reaction (PCR) amplification of leukemia-specific targets. 6,8 Of the various PCR techniques, limiting dilution analysis [9][10][11] and comparative hybridization methods [12][13][14] have been used the most.…”

Section: Introductionmentioning

confidence: 99%

“…6,7 The most common method for quantifying leukemic cells in ALL is polymerase chain reaction (PCR) amplification of leukemia-specific targets. 6,8 Of the various PCR techniques, limiting dilution analysis [9][10][11] and comparative hybridization methods [12][13][14] have been used the most. However, these methods are cumbersome and time-consuming.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay

et al. 2001

View full text Add to dashboard Cite

Hematologic relapse remains the greatest obstacle to the cure of children with acute lymphoblastic leukemia (ALL). Recent studies have shown that patients with increased risk of relapse can be identified by measuring residual leukemic cells, called minimal residual disease (MRD), during clinical remission. Current PCR methods, however, for measuring MRD are cumbersome and time-consuming. To improve and simplify MRD assessment, we developed a real-time quantitative PCR (RQ-PCR) assay for detection of leukemic cells that harbor the TAL-1 deletion. We studied serial dilutions of leukemic DNA and found the assay had a sensitivity of detection of one leukemic cell among 100 000 normal cells. We then investigated 23 samples from eight children with ALL in clinical remission. We quantified residual leukemic cells by using the TAL-1 RQ-PCR assay and by using limiting dilution analysis. In 17 samples, both methods detected MRD levels у0.001%. The percentages of leukemic cells measured by the two methods correlated well (r 2 ‫؍‬ 0.926). In the remaining six samples, both methods detected fewer than 0.001% leukemic cells. We conclude the TAL-1 RQ-PCR assay can be used for rapid, sensitive and accurate assessment of MRD in T-lineage ALL with the TAL-1 deletion. Leukemia (2001) 15, 166-170.

show abstract

Investigation of Minimal Residual Disease in Childhood and Adult Acute Lymphoblastic Leukaemia by Molecular Analysis

Cited by 105 publications

References 158 publications

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia

Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay

Contact Info

Product

Resources

About